JP2016513069A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513069A5
JP2016513069A5 JP2015540830A JP2015540830A JP2016513069A5 JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5 JP 2015540830 A JP2015540830 A JP 2015540830A JP 2015540830 A JP2015540830 A JP 2015540830A JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5
Authority
JP
Japan
Prior art keywords
formulation
aqueous
dvd
protein
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513069A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/068110 external-priority patent/WO2014071212A2/en
Publication of JP2016513069A publication Critical patent/JP2016513069A/ja
Publication of JP2016513069A5 publication Critical patent/JP2016513069A5/ja
Pending legal-status Critical Current

Links

JP2015540830A 2012-11-01 2013-11-01 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 Pending JP2016513069A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721364P 2012-11-01 2012-11-01
US61/721,364 2012-11-01
US201361794231P 2013-03-15 2013-03-15
US61/794,231 2013-03-15
PCT/US2013/068110 WO2014071212A2 (en) 2012-11-01 2013-11-01 Stable dual variable domain immunoglobulin protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118152A Division JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Publications (2)

Publication Number Publication Date
JP2016513069A JP2016513069A (ja) 2016-05-12
JP2016513069A5 true JP2016513069A5 (enExample) 2016-12-22

Family

ID=49585619

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015540830A Pending JP2016513069A (ja) 2012-11-01 2013-11-01 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2019118152A Pending JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2020178626A Pending JP2021020943A (ja) 2012-11-01 2020-10-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019118152A Pending JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2020178626A Pending JP2021020943A (ja) 2012-11-01 2020-10-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Country Status (15)

Country Link
US (3) US20140161817A1 (enExample)
EP (2) EP2914626A2 (enExample)
JP (3) JP2016513069A (enExample)
KR (1) KR20150079866A (enExample)
CN (1) CN105431453A (enExample)
AU (3) AU2013337644A1 (enExample)
BR (1) BR112015009924A2 (enExample)
CA (1) CA2889488A1 (enExample)
HK (1) HK1213204A1 (enExample)
IL (2) IL238264A0 (enExample)
MX (2) MX2015005495A (enExample)
RU (2) RU2015120605A (enExample)
SG (2) SG11201503324WA (enExample)
TW (3) TW202033215A (enExample)
WO (1) WO2014071212A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之dll4結合蛋白質
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
WO2015138337A1 (en) * 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
WO2015191760A2 (en) 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201639596A (zh) 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
CA2998740A1 (en) * 2015-09-17 2017-03-23 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
JP7112327B2 (ja) * 2015-12-29 2022-08-03 アウトルック セラピューティクス,インコーポレイティド ベバシズマブの緩衝された製剤
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
CN108261544B (zh) * 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261391B (zh) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
EP3658183A1 (en) 2017-07-28 2020-06-03 H. Hoffnabb-La Roche Ag Bispecific antibody formulation
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019197607A1 (en) * 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Fc-engineered anti-human ige antibodies and methods of use
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术(上海)有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113082203B (zh) * 2020-01-09 2023-10-20 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
EP4147711A4 (en) * 2020-04-20 2024-04-24 Shionogi & Co., Ltd Formulation containing hmgb1 partial peptide
AU2021377176A1 (en) * 2020-11-11 2023-06-22 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
WO2022113105A1 (en) * 2020-11-25 2022-06-02 Dr. Reddy's Laboratories Limited Stable therapeutic protein formulation and methods of making the same
WO2025231015A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof
CN120346170A (zh) * 2025-03-13 2025-07-22 武汉友芝友生物制药股份有限公司 抗EpCAM和CD3双特异性抗体药物组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CZ283717B6 (cs) 1991-03-06 1998-06-17 MERCK Patent Gesellschaft mit beschränkter Haftung Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
KR100317188B1 (ko) 1996-02-09 2002-02-19 스타르크, 카르크 사람TNFα와결합하는사람항체
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001062931A2 (en) 2000-02-25 2001-08-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
US20040091485A1 (en) 2000-05-19 2004-05-13 Ellis John Robert Maxwell Humanised antibodies to the epidermal growth factor receptor
CZ2003291A3 (cs) * 2000-06-29 2003-05-14 Abbott Laboratories Duálně specifické protilátky a způsoby jejich výroby a použití
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007257692B2 (en) * 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
NZ589434A (en) * 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
NZ603698A (en) * 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TR201903279T4 (tr) * 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
US8841417B2 (en) * 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
WO2012061374A2 (en) * 2010-11-02 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP6009455B2 (ja) * 2010-12-21 2016-10-19 アッヴィ・インコーポレイテッド Il−1アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用

Similar Documents

Publication Publication Date Title
JP2016513069A5 (enExample)
JP2016512050A5 (enExample)
JP2012045397A5 (enExample)
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2014003370A1 (es) Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición.
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
PL3060229T3 (pl) Stabilne, wodne formulacje przeciwciała
AR098168A1 (es) Formulación estable de insulina glulisina
TWD168530S (zh) 容器
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
TWD167749S (zh) 電連接器
JP2015525307A5 (enExample)
JP2013535391A5 (enExample)
JP2013227283A5 (enExample)
CY1123536T1 (el) Τρυγικο αλας του 5-χλωρο-θειοφαινο-2-καρβοξυλικου οξεος [(s)-2-[meθyλo-3-(2-oξo-πυρρολιδιν-1-υλ)-βενζολοσουλφονυλαμινο]-3-(4-μεθυλο-πιπεραζιν-1-υλ)-3-οξο-προπυλ]αμιδιου
JP2012186616A5 (enExample)
JP2016107746A5 (enExample)
JP2014159381A5 (enExample)
TWD162138S (zh) 眼鏡(二)
CN302314221S (zh) 眼镜(026)
CN302314225S (zh) 眼镜(tw14)
CN302314211S (zh) 眼镜(tw21)
CN302314208S (zh) 眼镜(tw13)
TWD175622S (zh) 可摺疊髮梳
CN302586459S (zh) 燃气灶(7)